BMO Capital Markets Sees Strong Investment Opportunities in MedTech Stocks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 11 hours ago
0mins
Source: seekingalpha
- Investment Opportunities in MedTech: BMO Capital Markets has identified Intuitive Surgical (ISRG), Globus Medical (GMED), and Teleflex (TFX) as high-conviction picks in the MedTech sector, noting that current stock prices are approximately 31% below their 10-year relative average, presenting a compelling buying opportunity for investors.
- Market Performance Analysis: Analyst Vik Chopra highlighted that despite the underperformance of MedTech stocks, their fundamentals remain robust, with broad-based first-quarter beats, attributing the weakness primarily to fund flows and policy noise rather than fundamental issues.
- Revaluation Potential: Chopra argues that the MedTech sector is under-owned and under-appreciated, with the marginal buyer absent as funds have rotated into AI and tech, emphasizing the importance of owning “best-in-breed franchises” ahead of a potential re-rating, which underscores the sector's investment appeal.
- Price Target Setting: Chopra has set price targets of $518, $94, and $159 for Intuitive Surgical, Globus Medical, and Teleflex respectively, reflecting his confidence in their strong fundamentals and future growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ISRG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ISRG
Wall Street analysts forecast ISRG stock price to rise
20 Analyst Rating
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 415.100
Low
575.00
Averages
637.32
High
740.00
Current: 415.100
Low
575.00
Averages
637.32
High
740.00
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BMO Capital Markets Sees Strong Investment Opportunities in MedTech Stocks
- Investment Opportunities in MedTech: BMO Capital Markets has identified Intuitive Surgical (ISRG), Globus Medical (GMED), and Teleflex (TFX) as high-conviction picks in the MedTech sector, noting that current stock prices are approximately 31% below their 10-year relative average, presenting a compelling buying opportunity for investors.
- Market Performance Analysis: Analyst Vik Chopra highlighted that despite the underperformance of MedTech stocks, their fundamentals remain robust, with broad-based first-quarter beats, attributing the weakness primarily to fund flows and policy noise rather than fundamental issues.
- Revaluation Potential: Chopra argues that the MedTech sector is under-owned and under-appreciated, with the marginal buyer absent as funds have rotated into AI and tech, emphasizing the importance of owning “best-in-breed franchises” ahead of a potential re-rating, which underscores the sector's investment appeal.
- Price Target Setting: Chopra has set price targets of $518, $94, and $159 for Intuitive Surgical, Globus Medical, and Teleflex respectively, reflecting his confidence in their strong fundamentals and future growth potential.
See More
Latest Analyst Ratings on Wall Street
- Nvidia Rating Reaffirmed: Citi maintains its Buy rating on Nvidia, citing strong access to DRAM memory amidst constrained industry supply, which positions the company favorably in the data center semiconductor market.
- Sarepta Upgrade: Wolfe upgrades Sarepta from Peer Perform to Outperform, believing that the current market regime and stock setup will lead to a rebound in its stock price, despite previous gains being transient.
- Comfort Systems Buy Rating: Goldman Sachs initiates coverage of Comfort Systems USA with a Buy rating and a 12-month price target of $2,159, implying a 28% upside, as the company is well-positioned for the AI infrastructure buildout.
- Salesforce Downgrade: KeyBanc downgrades Salesforce from Overweight to Sector Weight due to negative survey results indicating poor customer feedback, leading to a reduction in estimates and a lack of momentum in the company's performance.
See More
U.S. Healthcare Spending Reaches $5.7 Trillion Amid Growth Trends
- Healthcare Spending Surge: The U.S. healthcare sector reached $5.7 trillion in 2024, reflecting a 7.3% increase from the previous year, driven by higher consumption of medical products and services, indicating robust demand and long-term growth potential in the industry.
- Eli Lilly's Market Leadership: Eli Lilly leads the GLP-1 drug market, with strong sales from diabetes and weight-loss medications like Mounjaro, resulting in revenue and earnings growth that outpaces peers, and it is expected to solidify its market position further.
- Intuitive Surgical's Growth Prospects: Intuitive Surgical excels in robotic-assisted surgery with its da Vinci system, which enhances minimally invasive procedures; despite facing competition and tariff pressures, the company is well-positioned for sustained growth due to high switching costs and pricing power.
- AI Integration in Drug Development: Eli Lilly is increasingly leveraging artificial intelligence in drug development, which may lower R&D costs and boost profits, thereby enhancing its competitive edge in the rapidly evolving healthcare market.
See More
Eli Lilly and Intuitive Surgical's Growth Potential
- Healthcare Spending Surge: The U.S. healthcare sector reached $5.7 trillion in 2024, reflecting a 7.3% year-over-year increase, indicating a sustained rise in consumer demand for medical products and services, which provides long-term growth opportunities for related companies.
- Eli Lilly's Market Leadership: Eli Lilly's GLP-1 drugs, including Mounjaro and Foundayo, are achieving strong sales, driving the company's revenue and earnings growth rates above those of peers, showcasing its formidable competitive position in the diabetes and weight-loss drug markets.
- Intuitive Surgical's Technological Edge: Intuitive Surgical's da Vinci system leads the robotic-assisted surgery market, improving patient outcomes through minimally invasive procedures; despite facing competition and tariff pressures, the company possesses significant market expansion potential.
- AI Integration: Eli Lilly is leveraging artificial intelligence in drug development, a strategy that may lower R&D costs and enhance long-term profitability, further solidifying its leadership in the healthcare sector.
See More
Intuitive Surgical's Growth Potential Remains Strong
- Market Leadership: Intuitive Surgical's Da Vinci surgical robot has become the global market leader since its launch in 2000, with an installed base now reaching 11,395 systems, reflecting a 12% year-over-year increase, indicating the company's strong foundation and ongoing growth potential in minimally invasive surgery.
- Diverse Revenue Streams: In the recent quarter, Intuitive Surgical generated $650 million from system sales while bringing in $1.6 billion from instruments and accessories, showcasing the sustainability of its business model and the strength of its recurring revenue stream.
- Future Growth Forecast: For Intuitive Surgical to reach a market cap of $500 billion by 2031, its stock would need to rise 200% to about $1,500; considering its revenue nearly doubled over the past five years, maintaining similar growth could lead to annual revenue of $20 billion, enhancing the company's valuation.
- Technological Innovation Driving Growth: The newly launched Da Vinci 5 system features 150 design innovations and significant computing power, expected to improve operating room workflows and enhance surgeon autonomy, thereby driving revenue growth in the upcoming quarters.
See More
Intuitive Surgical: Significant Future Growth Potential
- Market Leadership: Intuitive Surgical's Da Vinci surgical robot, launched in 2000, has become the global market leader, widely used for various minimally invasive surgeries, ensuring the company's strong competitive advantage in the medical device industry.
- System Installation Growth: In the recent quarter, the number of installed Da Vinci systems reached 11,395, a 12% increase year-over-year, while global procedures grew by 16%, indicating the company's ongoing market expansion and profitability enhancement.
- Diverse Revenue Streams: In the recent quarter, Intuitive Surgical generated $650 million from system sales and $1.6 billion from instrument and accessory sales, demonstrating the sustainability of its business model and future growth potential.
- Future Market Forecast: It is predicted that by 2031, Intuitive Surgical's market capitalization could reach $500 billion, requiring a 200% increase in stock price to about $1,500 per share, reflecting the company's long-term investment value in the surgical robotics sector.
See More
BMO Capital Markets Sees Strong Investment Opportunities in MedTech Stocks
- Investment Opportunities in MedTech: BMO Capital Markets has identified Intuitive Surgical (ISRG), Globus Medical (GMED), and Teleflex (TFX) as high-conviction picks in the MedTech sector, noting that current stock prices are approximately 31% below their 10-year relative average, presenting a compelling buying opportunity for investors.
- Market Performance Analysis: Analyst Vik Chopra highlighted that despite the underperformance of MedTech stocks, their fundamentals remain robust, with broad-based first-quarter beats, attributing the weakness primarily to fund flows and policy noise rather than fundamental issues.
- Revaluation Potential: Chopra argues that the MedTech sector is under-owned and under-appreciated, with the marginal buyer absent as funds have rotated into AI and tech, emphasizing the importance of owning “best-in-breed franchises” ahead of a potential re-rating, which underscores the sector's investment appeal.
- Price Target Setting: Chopra has set price targets of $518, $94, and $159 for Intuitive Surgical, Globus Medical, and Teleflex respectively, reflecting his confidence in their strong fundamentals and future growth potential.
See More
Latest Analyst Ratings on Wall Street
- Nvidia Rating Reaffirmed: Citi maintains its Buy rating on Nvidia, citing strong access to DRAM memory amidst constrained industry supply, which positions the company favorably in the data center semiconductor market.
- Sarepta Upgrade: Wolfe upgrades Sarepta from Peer Perform to Outperform, believing that the current market regime and stock setup will lead to a rebound in its stock price, despite previous gains being transient.
- Comfort Systems Buy Rating: Goldman Sachs initiates coverage of Comfort Systems USA with a Buy rating and a 12-month price target of $2,159, implying a 28% upside, as the company is well-positioned for the AI infrastructure buildout.
- Salesforce Downgrade: KeyBanc downgrades Salesforce from Overweight to Sector Weight due to negative survey results indicating poor customer feedback, leading to a reduction in estimates and a lack of momentum in the company's performance.
See More
U.S. Healthcare Spending Reaches $5.7 Trillion Amid Growth Trends
- Healthcare Spending Surge: The U.S. healthcare sector reached $5.7 trillion in 2024, reflecting a 7.3% increase from the previous year, driven by higher consumption of medical products and services, indicating robust demand and long-term growth potential in the industry.
- Eli Lilly's Market Leadership: Eli Lilly leads the GLP-1 drug market, with strong sales from diabetes and weight-loss medications like Mounjaro, resulting in revenue and earnings growth that outpaces peers, and it is expected to solidify its market position further.
- Intuitive Surgical's Growth Prospects: Intuitive Surgical excels in robotic-assisted surgery with its da Vinci system, which enhances minimally invasive procedures; despite facing competition and tariff pressures, the company is well-positioned for sustained growth due to high switching costs and pricing power.
- AI Integration in Drug Development: Eli Lilly is increasingly leveraging artificial intelligence in drug development, which may lower R&D costs and boost profits, thereby enhancing its competitive edge in the rapidly evolving healthcare market.
See More
Eli Lilly and Intuitive Surgical's Growth Potential
- Healthcare Spending Surge: The U.S. healthcare sector reached $5.7 trillion in 2024, reflecting a 7.3% year-over-year increase, indicating a sustained rise in consumer demand for medical products and services, which provides long-term growth opportunities for related companies.
- Eli Lilly's Market Leadership: Eli Lilly's GLP-1 drugs, including Mounjaro and Foundayo, are achieving strong sales, driving the company's revenue and earnings growth rates above those of peers, showcasing its formidable competitive position in the diabetes and weight-loss drug markets.
- Intuitive Surgical's Technological Edge: Intuitive Surgical's da Vinci system leads the robotic-assisted surgery market, improving patient outcomes through minimally invasive procedures; despite facing competition and tariff pressures, the company possesses significant market expansion potential.
- AI Integration: Eli Lilly is leveraging artificial intelligence in drug development, a strategy that may lower R&D costs and enhance long-term profitability, further solidifying its leadership in the healthcare sector.
See More
Intuitive Surgical's Growth Potential Remains Strong
- Market Leadership: Intuitive Surgical's Da Vinci surgical robot has become the global market leader since its launch in 2000, with an installed base now reaching 11,395 systems, reflecting a 12% year-over-year increase, indicating the company's strong foundation and ongoing growth potential in minimally invasive surgery.
- Diverse Revenue Streams: In the recent quarter, Intuitive Surgical generated $650 million from system sales while bringing in $1.6 billion from instruments and accessories, showcasing the sustainability of its business model and the strength of its recurring revenue stream.
- Future Growth Forecast: For Intuitive Surgical to reach a market cap of $500 billion by 2031, its stock would need to rise 200% to about $1,500; considering its revenue nearly doubled over the past five years, maintaining similar growth could lead to annual revenue of $20 billion, enhancing the company's valuation.
- Technological Innovation Driving Growth: The newly launched Da Vinci 5 system features 150 design innovations and significant computing power, expected to improve operating room workflows and enhance surgeon autonomy, thereby driving revenue growth in the upcoming quarters.
See More
Intuitive Surgical: Significant Future Growth Potential
- Market Leadership: Intuitive Surgical's Da Vinci surgical robot, launched in 2000, has become the global market leader, widely used for various minimally invasive surgeries, ensuring the company's strong competitive advantage in the medical device industry.
- System Installation Growth: In the recent quarter, the number of installed Da Vinci systems reached 11,395, a 12% increase year-over-year, while global procedures grew by 16%, indicating the company's ongoing market expansion and profitability enhancement.
- Diverse Revenue Streams: In the recent quarter, Intuitive Surgical generated $650 million from system sales and $1.6 billion from instrument and accessory sales, demonstrating the sustainability of its business model and future growth potential.
- Future Market Forecast: It is predicted that by 2031, Intuitive Surgical's market capitalization could reach $500 billion, requiring a 200% increase in stock price to about $1,500 per share, reflecting the company's long-term investment value in the surgical robotics sector.
See More
